Literature DB >> 2787257

Development of large spleno-adreno-renal shunt after endoscopic sclerotherapy.

J B Dilawari1, G S Raju, Y K Chawla.   

Abstract

Endoscopic sclerotherapy is now a well-established form of treatment for bleeding esophageal varices. However, it is not known what effect obliteration of varices has on the development of natural portosystemic shunts. We have studied 15 patients bleeding from esophageal varices due to extrahepatic portal venous obstruction with splenoportovenography, before and after endoscopic obliteration of varices. A splenorenal (natural) shunt was defined when the contrast, injected into the spleen, immediately revealed the inferior vena cava. Such shunts were seen in 6 (40%) of 15 patients after the obliteration of esophageal varices and with a mean interval between the two sessions of splenoportovenography of 23.5 mo. In contrast, none of the 13 patients with bleeding due to extrahepatic portal venous obstruction developed splenorenal shunts (p less than 0.05) in the absence of treatment over a mean period of 40.8 mo. After obliteration, reappearance of esophageal varices requiring sclerotherapy was observed only in patients who did not develop shunts (p less than 0.05). In conclusion, natural splenorenal shunts were seen frequently in a group of patients with extrahepatic portal venous obstruction observed for 23.5 mo who also underwent sclerotherapy. It appears that splenorenal shunts result from sclerotherapy, and protect patients from rebleeding and recurrence of varices.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787257     DOI: 10.1016/0016-5085(89)90078-4

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  14 in total

1.  Effect of spontaneous portosystemic shunts on hemorrhage from esophagogastric varices.

Authors:  Jan-Sing Hsieh; Jaw-Yuan Wang; Che-Jen Huang; Fang-Ming Chen; Tsung-Jen Huang
Journal:  World J Surg       Date:  2003-12-05       Impact factor: 3.352

2.  Acquired intrahepatic portal vein aneurysm.

Authors:  T Yamaguchi; Y Kubota; T Seki; K Kunieda; M Ogura; T Mizuno; K Inoue; T Katoh
Journal:  Dig Dis Sci       Date:  1992-11       Impact factor: 3.199

Review 3.  Hepatology in India and INASL: A Ringside View.

Authors:  Anil C Anand
Journal:  J Clin Exp Hepatol       Date:  2012-09-21

4.  Study of hemodynamic changes in portal systemic shunts and their relation to variceal relapse after endoscopic variceal ligation combined with ethanol sclerotherapy.

Authors:  Kenji Ito; Shoichi Matsutani; Hitoshi Maruyama; Taro Akiike; Hiromasa Nomoto; Toshiya Suzuki; Takeshi Fukuzawa; Hideaki Mizumoto; Hiromitsu Saisho
Journal:  J Gastroenterol       Date:  2006-02       Impact factor: 7.527

5.  Role of paraoesophageal collaterals and perforating veins on outcome of endoscopic sclerotherapy for oesophageal varices: an endosonographic study.

Authors:  R K Dhiman; G Choudhuri; V A Saraswat; D K Agarwal; S R Naik
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

Review 6.  Portal vein thrombosis.

Authors:  Yogesh K Chawla; Vijay Bodh
Journal:  J Clin Exp Hepatol       Date:  2015-01-06

7.  Portal hypertension in north Indian children.

Authors:  N K Arora; R Lodha; S Gulati; A K Gupta; P Mathur; M S Joshi; N Arora; D K Mitra
Journal:  Indian J Pediatr       Date:  1998 Jul-Aug       Impact factor: 1.967

8.  Surgical treatment of massive splenomegaly and severe hypersplenism secondary to extrahepatic portal venous obstruction in children.

Authors:  Roy Choudhury Subhasis; Chadha Rajiv; Sharma Akshay Kumar; Anand Vinod Kumar; Patwari Ashok Kumar
Journal:  Surg Today       Date:  2007-01-01       Impact factor: 2.549

9.  Sclerotherapy in noncirrhotic portal fibrosis.

Authors:  Y K Chawla; J B Dilawari; R K Dhiman; M K Goenka; D K Bhasin; R Kochhar; K Singh; U Kaur
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

10.  Combined (short-term plus longterm) sclerotherapy v short-term only sclerotherapy: a randomised prospective trial.

Authors:  M Moretó; M Zaballa; E Ojembarrena; S Ibáñez; M J Suárez; F Setién; E Delgado
Journal:  Gut       Date:  1994-05       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.